Biomarkers such as tumor-infiltrating lymphocytes in the tumor immune microenvironment (TIME), programmed death-1 ligand (PD-L1) expression, KRAS alteration, and TGFBR2 may predict the efficacy of pharmacotherapy including ICIs for biliary tract cancer [14]. This evidence concerns the gene KRAS and neoplasm.